Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Christopher Chiu | Researchclopedia

Back to researchers

Christopher Chiu

The University of Sydney ORCID

52

Works

9,728

Citations

30

h-index

39

i10-index

Research Topics

Multiple Myeloma Research and Treatments Peptidase Inhibition and Analysis Protein Degradation and Inhibitors

Affiliations

The University of Sydney2024–2025

University of Leeds2019–2019

Harvard University2017–2017

Janssen (Belgium)2017–2017

University of California, San Francisco2006–2011

Top Works

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos,Albert Oriol,et al.

20161,421 citations

Monoclonal and Polyclonal Antibodies Research

Chronic Lymphocytic Leukemia Research

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon,Shaji Kumar,et al.

2019974 citations

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos,Meletios Α. Dimopoulos,et al.

2017973 citations

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau,Michel Attal,et al.

2019938 citations

Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis

Hiroaki Nozawa,Christopher Chiu,et al.

2006916 citations

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont,Tycel Phillips,et al.

2022494 citations

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Ajai Chari,Attaya Suvannasankha,et al.

2017441 citations

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof,Tineke Casneuf,et al.

2016373 citations

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings,Rogier Mous,et al.

2021319 citations